At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Commentary|Articles|August 7, 2026
Q&A: Prepare for FDA Inspection on Compounded GLP-1s
Fact checked by: Ron Panarotti
Pharmacists can guide patients in verifying sources, identifying licensed pharmacies, and understanding compounded vs FDA-approved products.
Advertisement
Advertisement
Annie Lambert, PharmD, BCSCP, compliance program manager at Wolters Kluwer Health, discussed the shifting regulatory landscape around compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and what it means for pharmacists. She explained that by excluding GLP-1s from the 503B bulk compounding list, the FDA is signaling a narrower role for widespread compounding of agents like semaglutide (Ozempic, Wegovy; Novo Nordisk), tirzepatide (Mounjaro, Zepbound; Eli Lilly and Company), and liraglutide (Victoza, Saxenda; Novo Nordisk), while 503A pharmacies face increased scrutiny.
Related to this article
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
Advertisement
Advertisement